 TRACON Pharmaceuticals NASDAQ:TCON Inc announced that the amended ENVASARC protocol approved by the US Food and Drug Administration FDA in February has now been approved by institutional review boards or ethics committees at all 30 of its clinical sites, including 29 in the US and one in the UK. The San Diego-based clinical stage biopharmaceutical company said it expects to report results of Independent Data Monitoring Committee IDMC mandated interim safety reviews and interim efficacy review in the second half of 2022. 